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ABSTRACT
A 21 year old woman (G2 P0101) of24 weeks gestation presented with syphilis ofunknown duration.
Sonography revealed fetal hydrops and placental thickening. Weekly intramuscular injections of2.4
million U Bicillin for 3 weeks was initiated as recommended by the Centers for Disease Control.
Repeat sonogram 1 week after starting treatment revealed increased ascites and a new pericardial
effusion. Due to the worsening fetal condition, therapy was altered and the patient was admitted for
IV penicillin. She received a continuous infusion of 18 millionU penicillinG daily for 10 days. Serial
sonograms showed improvement offetal ascites and pericardial effusion with 10 days ofIV therapy,
and complete resolution of hydrops was noted within 3 weeks. The fetus was born at term with no
stigmata ofcongenital syphilis on newborn exam, and laboratory tests suggested adequate treatment
in utero. (C) 1993 Wiley-Liss, Inc.
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n 1987 the incidence of syphilis reached its high-
est peak since 1950. This increase was greater in
women than men, regardless of ethnic group.
Furthermore, the increase in congenital syphilis
paralleled the rise in women.
2 Benzathine penicil-
lin G is considered the treatment of choice for
maternal infection by the Centers for Disease Con-
trol (CDC); it prevents neonatal infection in 97-
100% of cases.
3-5 However, if there is reinfection,
severe infection, or treatment late in pregnancy
(second or third trimester), treatment failure can
occur. 5’6 The CDC has reported that these failures
are responsible for 35% of neonatal infections. 2’7
In the past 20 years, no prospective, randomized
study evaluating fetal syphilotherapy has been pub-
lished, s,7
Left untreated, congenital syphilis has signifi-
cant perinatal morbidity and mortality, with re-
ported mortality rates of 40-54%.
1,8,9 Treatment
failure in severe fetal infection may result in fetal
death. 3’5 In a recent case report, Hallak et al. at-
tempted to treat a hydropic fetus with high-dose IV
penicillin.
10 They were unable to complete therapy
due to fetal distress during fetal blood transfusion
that resulted in an emergent cesarean section. We
describe a pregnancy with a severely affected fetus
that had complete resolution of fetal hydrops and
placental thickening 3 weeks after initiation of ma-
ternal IV infusion of penicillin G with no clinical
stigmata of congenital syphilis identified at birth.
CASE REPORT
A 21 year old black woman (G2P0101) at 24 weeks
gestation by menstrual and ultrasound dating was
diagnosed with syphilis ofunknown duration at her
initial prenatal visit with the local health depart-
ment. There was no prior history of syphilis. Her
obstetrical history was complicated by prior pre-
term delivery at 36 weeks gestation in which serol-
ogy testing for syphilis was negative. She had had
multiple sexual contacts in the past. Her rapid
plasma reagin (RPR) was 1:64 and microhemag-
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Fig. I. Fetal sonograms prior to high-dose intravenous penicillin. .: Disproportion of fetal abdo-
men to thorax. Echodensities in the bowel (arrows). Ascites noted in periphery of abdomen. !
Dilated loops of small bowel within marked ascites. C: Thickened placenta measuring 5-7 cm. D:
Pericardial effusion (arrows).
glutination assay for antibodies to Treponema palli-
dum (MHATP) was reactive. Spinal tap was not
performed because of a normal neurologic exami-
nation. She was started on weekly injections of 2.4
million U of Bicillin for 3 weeks as recommended
by the CDC for syphilis of unknown duration. An
ultrasound performed at the start of therapy re-
vealed fetal hydrops and placental thickening, an
enlarged liver, intestinal echodensities, and di-
lated loops of small bowel. Parvovirus B-19 titers
showed immunity. A repeat ultrasound 8 days after
initiation of therapy revealed a pericardial effusion
and progression of the ascites (Fig. 1).
Due to worsening fetal conditions despite week
of Bicillin treatment, the patient was admitted to
the antepartum service for aggressive IV penicillin
G therapy with doses routinely used to treat adult
neurosyphilis. Daily penicillin G at 18 million U
continuous IV infusion was initiated and continued
for 10 days. The patient tolerated treatment well
and remained afebrile throughout her hospitaliza-
tion. She did not experience the Jarisch-Herxhe-
imer reaction other than a few uterine contractions
requiring no tocolysis. No fetal heart rate abnor-
malities were noted during episodic monitoring.
Serial ultrasound was performed throughout the
hospitalization. After 4 days of therapy the ascites
and pericardial effusion were unchanged. Six days
after therapy there was slight improvement of the
ascites. On day 8 of therapy significant improve-
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Fig. 2. Fetal sonograms 3 weeks following initiation of high-dose intravenous penicillin. A: Resolu-
tion of ascites. I: Normal-appearing placenta.
ment of both ascites and pericardial effusion were
noted. On the day of discharge, following 10 days
of IV penicillin, ultrasound revealed even less as-
cites and the pericardial effusion was just detect-
able. Three weeks after initiation of treatment, fol-
low-up ultrasound revealed complete resolution of
fetal hydrops and placental thickening (Fig. 2).
There was good interval growth, and the placenta
was no longer hydropic. Ultrasound was per-
formed at 2-4 week intervals until delivery, and all
remained normal.
The patient delivered at 37+ weeks gestation
after the onset of spontaneous labor. No stigmata of
congenital syphilis were evident on the newborn
examination. Complete blood count showed no ev-
idence of anemia or thrombocytopenia. Liver func-
tion tests were normal. Umbilical cord Venereal
Disease Research Laboratory (VDRL) titer was
1:2. Fluorescent treponemal antibody-absorption
(FTA-ABS) on serum was 3 + reactive. Cerebral
spinal fluid (CSF) VDRL was non-reactive, FTA-
ABS was 3+ reactive, and FTA-ABS IgM was
negative. CSF gram stain and cultures were nega-
tive. The CSF protein was elevated at 194 mg/dl
(normal 15-60), glucose was 37 mg/dl (normal
50-80), and the cell count was unremarkable. At
the 4- week check, the infant was doing well and had
surpassed its birth weight. Repeat VDRL was
weakly reactive with 0 dilutions. Repeat CSF stud-
ies showed an improved, yet persistantly elevated
protein of 123 mg/dl. At the 2 month check, the
infant was progressing well and was neurologically
intact. VDRL was nonreactive and FTA-ABS was
3+ reactive. It was felt that the infant had been
treated adequately in utero and that the decreasing
levels of CSF protein represented a normalizing
trend. However, because the consequences of early
childhood neurosyphilis are tragic and there was
concern about the ability to follow this child closely
over a longer period of time, the infectious disease
consult service chose to treat the child again with
200,000 U of aqueous penicillin G IM twice daily
for 14 days.
DISCUSSION
With the decline in incidence of Rh isoimmuniza-
tion, fetal hydrops is more commonly of infectious
origin. A review of the literature by Hallak et al.
revealed only 14 cases of nonimmune hydrops due
to syphilis. Other infectious etiologies of nonim-
mune hydrops sited were cytomegalovirus, bacte-
ria, toxoplasmosis, rubella, herpes, Listeria, and
Chlam2dia.
o Although fetal hydrops due to syphi-
lis is rare, it is likely to increase along with the
increasing incidence of congenital syphilis.
The current CDC recommended treatment for
syphilis in the pregnant individual is similar to that
of the nonpregnant individual.
9 The literature re-
flects uncertainty regarding the efficacy of this
treatment, as shown by the number of studies re-
porting treatment failures, which account for 35%
of neonatal infections. 2’s’6’2’ A well-controlled
evaluation of the current CDC-recommended
treatment for syphilis in pregnancy has not been
reported, in part because of our inability to mea-
sure the response of the disease to therapy.’s’6
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However, sonography is a mechanism by which the
response to therapy of the severely infected fetus
can be monitored.
In a 1988 publication, Wendel notes that
women treated in the late second or third trimester
of pregnancy may deliver affected infants prema-
turely or experience fetal demise soon after therapy,
the latter possibly occurring secondary to the
Jarisch-Herxheimer reaction. He also states that
benzathine penicillin may prevent congenital syph-
ilis, but that it may not alter the course of severe
fetal disease. Several reports have documented high
perinatal mortality with fetal hydrops due to syphi-
lis.
14-17 The hydropic fetus has a poor prognosis in
spite of having a treatable infection, hence the deci-
sion for aggressive parenteral therapy of the
mother.
Newborns with congenital syphilis can present
with overwhelming, multisystem infection or be
entirely asymptomatic, with the only diagnostic test
a positive serology. The severely infected syphilitic
fetus demonstrates hepatosplenomegaly, skin and
scalp edema, ascites, pleural effusion and fibrosis,
cardiac effusion, gastrointestinal adhesions, and he-
matopoietic changes.
18 Ultrasound can detect and
monitor placental thickening, hepatomegaly, as-
cites, hydrops, and small bowel dilatation. 14,19--22
Cordocentesis has been used in a small number of
cases. These infected fetuses demonstrate anemia,
thrombocytopenia, and elevated liver enzymes.
A recent study by Wendel et al. described a
hydropic fetus treated by current CDC recommen-
dations that had resolution of hydrops 4 weeks after
treatment. This fetus had mild hepatosplenomegaly
at birth and required additional treatment in the
neonatal period.
21 We describe placental thicken-
ing and progressive fetal hydrops that showed sono-
graphic evidence of improvement during high-
dose IV penicillin treatment with subsequent
complete resolution of hydrops 3 weeks after initia-
tion of therapy. The neonate was asymptomatic and
had biochemical evidence of treated syphilis infec-
tion.
Penicillin G carries a category B risk factor and
is commonly used in obstetrical infections. Prior to
1950, adverse fetal outcome due to maternal peni-
cillin G administration was reported, but was likely
due to impurities of the preparation. No evidence
of birth defects induced by penicillin G has been
documented. It passes rapidly into the fetal circula-
tion and amniotic fluid in therapeutic levels, except
in the first trimester, when levels may be subthera-
peutic in the amniotic fluid. Parenteral penicillin G
reaches equal levels in maternal serum and arnni-
otic fluid within 60-90 minutes.
23 Therefore,
doses that are normally used to treat adult neuro-
syphilis may attain serum and amniotic fluid levels
high enough to treat severe infections in utero.
The rapid response to high-dose penicillin G
therapy and lack of syphilis stigmata at birth sug-
gest that this means of treatment may serve a role in
the severely affected fetus, particularly late in preg-
nancy. The availability of high-resolution sonogra-
phy provides a means to closely monitor the re-
sponse of the disease to treatment closely. Further
investigation is warranted to evaluate the efficacy of
high-dose IV penicillin versus current CDC rec-
ommended treatments for the severely syphilitic
fetus.
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